陳建宏醫師詳細介紹

• 高雄長庚紀念醫院 內科部部主任 (2022.07)
• 高雄長庚紀念醫院 教授級主治醫師
• 長庚大學 醫學系兼任教授
• 高雄長庚紀念醫院PGY1內科導師、臨教
• 中華民國醫用超音波學會第20屆監事

• 中國醫藥學院醫學系畢
• 長庚大學臨床醫學研究所博士班畢

• 高雄長庚紀念醫院胃腸肝膽科系系主任
• 高雄長庚紀念醫院胃腸肝膽科系副系主任
• 高雄長庚紀念醫院內科部副部主任
• 縣立鳳山醫院委託高雄長庚醫院經營 胃腸肝膽科主治醫師
• 高雄長庚醫院胃腸科研究員
• 高雄長庚醫院內科部住院醫師
• 中華民國醫用超音波學會 第15屆、第17屆、第18屆理事、第19屆監事

• 台灣內科醫學會內科專科醫師及指導醫師
• 台灣消化系醫學會消化系內科專科醫師及指導醫師
• 台灣消化系內視鏡醫學會消化系內視鏡專科醫師及指導醫師
• 中華民國醫用超音波學會超音波專業醫師
• 台灣肝癌醫學會專科醫師
• 台灣醫學教育學會一般醫學師資

• Chen CH*, Tai WC, Hu TH, Wang JH, Hung CH, Lu SN. Patterns of Hepatitis B Virus Viremia Change and Hepatitis B Surface Antigen Loss Rate in Patients Without Retreatment Within 2 Years After Entecavir or Tenofovir Cessation. Am J Gastroenterol. 2025 Dec 1;120(12):2832-2839. (SCI)
  慢性B型肝炎病人停止貝樂克和惠立妥兩年後沒有再治療的病人B型肝炎病毒變化的型態和表面抗原消失的比例
  
• Fang HW, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Higher Relapse Rate in HBeAg-Negative Patients After Cessation of Tenofovir Alafenamide Compared With Entecavir or Tenofovir Disoproxil Fumarate. Am J Gastroenterol. 2025 Nov 1;120(11):2567-2575. (SCI)
  韋立得在慢性B型肝炎e抗原陰性病患停藥後比貝樂克和惠立妥有較高的復發率
  
• Huang PY, Lin YC, Wang CC, Chen CH*. Clinical outcomes and Predictors in Patients with Acute on Chronic Liver Failure in Southern Taiwan. J Formos Med Assoc. 2025 Mar;124(3):234-240. (SCI)
  南台灣急性加重慢性肝衰竭患者的臨床結果與預測因子
  
• Tsai MC, Kuo YH, Tai WC, Yao CC, Chuah SK, Kee KM, Wang JH, Chen CH*. Distinct gut microbiota alterations in patients with early-stage and advanced-stage hepatocellular carcinoma. Adv Dig Med. 2024 Dec;11:196-203.
  早期和晚期肝細胞癌患者腸道微生物群的不同變化
  
• Chen CH*, Wang JH, Lai HC, Hu TH, Hung CH, Lu SN, Peng CY*. Mac-2 binding protein glycosylation isomer at 5 years of antiviral therapy predict hepatocellular carcinoma and mortality beyond year 5 in chronic hepatitis Bpatients with cirrhosis. Am J Cancer Res. 2024 May 15;14(5):2465-2477. (SCI)
  慢性B型肝炎肝硬化病人用抗病毒藥治療五年的Mac-2結合蛋白糖基化異構體的值可以預測治療五年後病人發生肝癌和死亡
  
• Fang HW#, Tseng PL#(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy. Virol J. 2024 Apr 3;21(1):79. (SCI)
  B型肝炎癌症病人接受貝樂克或韋立得預防性用藥停藥後B型肝炎復發的比較
  s12985-024-02338-6.
• Sonneveld MJ, Chiu SM(Co first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Janssen HL, Berg T, Zoulim F, ....., Chen CH*, Maasoumy B*, CREATE Study Group. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy. Gastroenterology. 2024 Jan; 166(1):168-177.e8. (SCI)
  B型肝炎e抗原陰性病人停止抗病毒藥物後第24週的B型肝炎B型肝炎病毒量和表面抗原定量可以預測停藥後臨床復發和表面抗原消失
  
• Fang HW, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment. Dig Liver Dis. 2023 Sep;55(9):1223-1229. (SCI)
  停藥後B型肝炎表面抗原的下降可以預測e抗原陰性停貝樂克或惠立妥治療後沒有再治療病人高表面抗原消失的比率
  doi: 10.1016/j.dld.2023.02.006.
• Chen CH*, Peng CY, Hu TH, Wang JH, Hung CH, Lu SN. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023 Aug;58(3):334-345. (SCI)
  慢性型肝炎病人惠立妥停藥後比貝樂克停藥有較高的表面抗原消失率
  
• Sonneveld MJ, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bommel F, Berg T, Zoulim F, Hoon Ahn S, Dalekos GN, .......,Chen CH*, Maasoumy B*. CREATE study group Affiliations expnd. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study. JHEP Rep. 2023 Aug ;5(8):100790. (SCI)
  B型肝炎e抗原陰姓病人治療前較低的B型肝炎病毒量有較好的停止核甘酸類似物的預後
  
• Chen CH*, Jeng WJ(co-first), Hu TH, Liu YC, Wang JH, Hung CH, Lu SN, Chien RN. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis. 2023 Jun;55(6):771-777. (SCI)
  B型肝炎病人停止惠利妥有沒有轉換至韋利得治療B型肝炎病毒的復發率
  
• Wang HW, Chen CY, Lai HC, Hu TH, Su WP, Lu SN, Hung CH, Chuang PH, Wang JH, Chen CH*, Peng CY*. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy. Am J Cancer Res. 2023 Feb 15;13(2):526-537. (SCI)
  B型肝炎代償性肝硬化病人接受抗病毒藥治療發生肝癌的預測模式
  
• Chiu SM, Chang KC, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Dig Dis Sci. 2023 Feb;68(2):665-675. (SCI)
  韋立得、貝樂克和惠立妥對於貝樂克和惠立妥停藥後病人治療及再治療的療效和腎功能安全性的比較
  
• Tseng TN(co-first), Jeng WJ(co-first), Hu TH, Wang JH, Hung CH, Lu SN, Chen CH*. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother. 2023 Feb 1;78(2):436-439. (SCI)
  合併治療前B型肝炎核相關抗原和治療結束B型肝炎表面抗原可以預測貝樂克或惠立妥停藥後B型肝炎病毒的復發
  
• Liu YC, Jeng WJ, Chen CH*. Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1890-1891. (SCI) Letter to the Editor
  
  
• Chen CH*, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy. Cancers (Basel). 2022 Oct 16;14(20):5063. (SCI)
  以Mac-2 結合蛋白糖基化異構体為基礎建構的危險模式可以預測B肝肝硬化病人接受抗病毒藥物治療發生肝癌
  
• Tseng TN, Chen CH*. Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022 Sep;56(5):916-917. (SCI)
  慢性B型肝炎病人由惠立妥換成韋立得腎功能和骨質密度的變化
  
• Fang HW, Yen YH, Hung CH, Wang JH, Hu TH, Lu SN, Chen CH*. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Dig Dis Sci. 2022 Jul;67(7):3402-3411. (SCI)
  病人停藥貝樂克或惠立妥發生臨床復發後病毒抑制的預測因子
  
• Chen CH*, Peng CY, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN. Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients. J Infect Dis. 2022 Jun 1;225(11):1974-1981. (SCI)
  B型肝炎抗原陽性病人停止惠立妥比貝樂克有較早和較高的B型肝炎病毒復發率
  
• Tseng TN, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. Viruses. 2022 May 30;14(6):1189. (SCI)
  停止貝樂克和惠立妥後有病毒復發但無臨床復發病人表面抗原的變化
  
• Jeng WJ*, Chen CH*, Wang YW, Pan MH, Lin CW, Lin CY, Yang HI*. The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. Virol J . 2022 Mar 31;19(1):59. (SCI)
  
  
• Sonneveld MJ*, Chiu SM(co-first), Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bommel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Honer Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH*, Maasoumy B; Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. CREATE study group. J Hepatol. 2022 May;76(5):1042-1050. (SC
  停藥後依B型肝炎基因型和抗原來評估B型肝炎表面抗原消失的可能性
  
• Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH*. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma. 2021 Dec;62(12):2899-2906. (SCI)
  B型肝炎表面抗體的值在防止B型肝炎病人接受RITUXIMAB治療B型肝炎肝炎復發的角色
  
• Huang PY, Wang JH, Hung CH, Lu SN, Hu TH*, Chen CH*. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat. 2021 Aug;28(8):1141-1149. (SCI)
  B型肝炎病毒核心關連抗原預測B型肝炎e抗原陰性病患停用貝樂克後B型肝炎復發的角色
  
• Peng CY*, Chen CH*. On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B. Liver Int. 2021 Jul;41(7):1700-1701. (SCI)
  
  
• Kuo YH , Wang JH, Hung CH, Lu SN, Hu TH*,Chen CH*.Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int. 2021 Apr;15(2):301-309. (SCI)
  合併停藥時B肝表面抗原與基線B肝病毒核心相關抗原可減少惠立妥停藥後B肝復發率
  
• Chen CH*, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. Am J Cancer Res. 2020 Nov 1;10(11):3882-3895.
  台灣慢性B型肝炎肝硬化病人接受貝樂克或惠立妥治療後肝癌發生率的比較 :一個回溯性的研究
  
• Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, Chen CH*. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir therapy. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2989-2997.e3. (SCI)
  B型肝炎基因型B和C感染在貝樂克和惠立妥停藥後病毒復發的相關性
  （長庚醫院2020年度住院醫師優良論文獎第二名)
• Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, Jeng WJ*, Chen CH*. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clin Gastroenterol Hepatol. 2020 Nov;18(12):2803-2812.e2. (SCI)
  貝樂克和惠立妥停藥時表面抗原小於100IU/mL 的病人B型肝炎病毒復發的發生率和相關因子
  （長庚醫院2020年度住院醫師優良論文獎第一名)
• Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY*, Chen CH*. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020 Jul;14(4):513-520. (SCI)
  慢性B型肝炎病患接受貝樂克治療5年後發生肝癌的機率和預測因子
  
• Hsieh YC, Lin CL, Hung CH, Chen CH, Tung SY*, Lin CY, Hu TH, Lu SN, Chien RN, Sheen IS. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. J Viral Hepat. 2020 May;27(5):505-513. (SCI)
  
  
• Chen CH*, Hu TH, Wang JH, Lai HC, Hung CH, Lu SN, Peng CY*. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int. 2020 May;14(3):317-325. (SCI)
  B型肝炎抗原陰性病人停止和繼續貝樂克治療病人表面抗原的變化
  
• Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH*, Peng CY*. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers (Basel). 2020 May 7;12(5):1177. (SCI)
  慢性B型肝炎病人接受貝樂克治療治療一年後FIB-4值的變化可以幫助預測得到肝癌最低風險的病人
  
• Kuo YH, Wang JH, Chang KC, Hung CH, Lu SN, Hu TH, Yen YH, Kee KM, Chen CH*. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Invest New Drugs. 2020 Feb;38(1):202-210. (SCI)
  直接抗病毒藥物對C型肝炎相關肝癌經根除性治療後的影響
  
• Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One. 2019 Oct 4;14(10):e0222221. (SCI)
  慢性B型肝炎病人停止貝樂克和惠立妥治療後需再治療的發生率和預測因子
  
• Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH*. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci. 2019 Sep;64(9):2563-2569. (SCI)
  B型肝炎病毒前表面和表面抗原及核心啟動和前核心基因突變在慢性B型肝炎病人發生嚴重急性發作的角色
  
• Chen CH, Chen CH(co-first), Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH*, Sheen IS*. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir?±?ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep. 2019 May 8;9(1):7086. doi: 10.1038/s41598-019-43554-3. (SCI)
  Paritaprevir/ritonavir/ombitasvir/dasabuvir 加雷巴韋林在C型肝炎病毒基因1型合併晚期纖維化患者中的真實世界安全性和效用：多中心匯總分析
  
• Chen CH*, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY*. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019 Apr 19;219(10):1624-1633. (SCI)
  e抗原陰性慢性B型肝炎非肝硬化病人在貝樂克治療停藥後患者和持續治療貝樂克患者其表面抗原消失的比例
  
• Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH*, Peng CY*. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol. 2019 Feb;34(2):442-449. (SCI)
  用修改後的FIB-4指數來預測慢性B型肝炎病人接受貝樂克治療發生肝癌的分層風險
  
• Chen CH*. Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply. Aliment Pharmacol Ther. 2019 Apr;49(8):1106-1107. (SCI)
  
  
• Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, Chen CH*. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019 Jan;49(2):218-228. (SCI)
  慢性B型肝炎停止貝樂克或惠立妥治療後B型肝炎病毒的復發率
  
• Chiang HH, Lee CM, Hu TH, Hung CH, Wang JH, Lu SN, Lai HC, Su WP, Lin CH, Peng CY*, Chen CH*. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int. 2018 Nov;38(11):1997-2005. (SCI)
  結合治療中FIB-4和胎兒蛋白預測肝硬化病人治療貝樂克的臨床預後
  
• Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH*. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol. 2018 Oct;33(10):1766-1772. (SCI)
  B型肝炎表面抗原在癌症病人化療時接受貝樂克和惠立妥預防性治療停藥後預測B型肝炎病毒復發的角色
  
• Chen CH*, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018 Sep;24(9):997-1003. (SCI)
  
  
• Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, Hu TH*. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat. 2018 May;25(5):590-597. (SCI)
  
  
• Chen CH, Lee CM, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Wang JH, Lee MH, Peng CY*. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget. 2017 Sep 28;8(54):92431-92441. doi: 10.18632/oncotarget.21369. (SCI)
  
  
• Wu IT, Hu TH, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH*. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017 Jul;23(7):464-469. (SCI)
  
  
• Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH*. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat. 2017 Jul;24(7):599-607. (SCI)
  
  
• Chen CH*. Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals - incidence, severity of hepatitis and lessons to learn. Aliment Pharmacol Ther. 2017 May;45(10):1373-1374. doi: 10.1111/apt.14051. (SCI)
  慢性C型肝炎用直接抗病毒藥物治療B型肝炎病毒的復發—發生率，肝炎的嚴重度和經驗的教訓
  
• Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH*. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg???200?IU/mL. Sci Rep. 2017 May 12;7(1):1839. (SCI)
  
  
• Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH*, Chen CH*. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and -experienced chronic hepatitis B patients. J Gastroenterol Hepatol. 2016 Jul;31(7):1307-14. (SCI)
  
  
• Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM*. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2015 Nov;13(11):1984-1992. (SCI)
  
  
• Pei SN, Chen CH*. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma. 2015 Jun;56(6):1611-8. (SCI)
  
  
• Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH*. Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation. Antimicrob Agents Chemother. 2015 Jun;59(6):3168-73. (SCI)
  
  
• Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH*. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol. 2015 May;30(5):918-24. (SCI)
  
  
• Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM*. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014 Sep;61(3):515-22. (SCI)
  
  
• Kuo LF, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Chen CH*. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Dig Dis Sci. 2014 Oct;59(10):2580-7. (SCI)
  
  
• Chen CH, Hu TH, Hung CH, Wang JH, Lu SN, Lee CM*. Antiviral effect of entecavir in nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy. J Viral Hepat. 2014 Aug;21(8):e55-64. (SCI)
  
  
• Chen CH*, Lu SN, Lee CM, Hung CH, Wang JH, Hu TH. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion. Hepatol Int. 2014 July; 8(3): 365-374. (SCI)
  
  
• Chen CH, Lin CL(co-first), Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN*, Lee CM*. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014 Jun;60(6):1127-34. (SCI)
  
  
• Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH*. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014 Jun 28;20(24):7686-7695. (SCI)
  
  
• Tsai MC, Yu HC(co-first), Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH*, Hu TH*. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014 Mar;29(3):568-75. (SCI)
  
  
• Tsai MC, Chen CH*, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014 Feb;20(2):O90-O100. (SCI)
  
  
• Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH*. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013 Sep;68(9):2154-63. (SCI)
  
  
• Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM*. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naive and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013 July; 7(3):832-843. (SCI)
  
  
• Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH*. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int. 2013 June. 7(2):489-499. (SCI)
  
  
• Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN*. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int. 2013 June;7(2):477-488. (SCI)
  
  
• Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH*. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012 Jul;91(7):1007-12. (SCI)
  
  
• Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM*. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. Antivir Ther. 2012;17(4):701-9. (SCI)
  
  
• Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN*. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011 Mar;26(3):461-8. (SCI)
  
  
• Chen CH, Chiu YC, Chou YP, Kuo CM, Wu KL, Chuah SK*. Cronkhite-Canada Syndrome: Report of a Case. Gastroenterol J Taiwan. 2011 Mar;28(1):57-61.
  
  
• Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM*. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. Liver Int. 2011 Feb;31(2):206-14. (SCI)
  
  
• Chen CH, Lee CM*, Tung WC, Wang JH, Hung CH, Hu TH, Wang JC, Lu SN, Changchien CS. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol. 2010 Apr;52(4):478-85.(SCI)
  
  
• Chen CH, Changchien CS, Lee CM*, Tung WC, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer. 2009 Aug 1;125(3):621-9. (SCI)
  
  
• Lin MT, Kuo YH, Chuah SK, Chiu YC, Huang CC, Tai WC, Chen CH*, Lee CM. Mantle cell lymphoma with diffuse gastrointestinal tract involvement: A case report. J Internal Medicine of Taiwan 2009 Dec;20(6):555-560.
  
  
• Chen CH, Changchien CS, Lee CM*, Hung CH, Hu TH, Wang JH, Wang JC, Lu SN. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis. 2008 Dec 1;198(11):1634-42. (SCI)
  
  

陳建宏醫師的評價

陳建宏醫師的看診評價，你對醫師的看法、看診經曆，都可以在這裏發表!

發表您的評價